Duan, J., Zhong, J., Sun, B., Zhao, W., Wu, L., Fei, K., Chu, Q., Guo, Q., Song, Q., Yu, Y., Zhu, D., Liu, X., Zhao, J., Zhan, Z., Li, S., Nie, L., Lin, J., Peng, X., Zhong, D., Zhou, J., Li, L., Chen, Y., Hu, C., Mok, T., Wang, Z., Wang, J. (2026). Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with
                    <i>EGFR</i>
                    and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.70071